Fundraising FoxThyreos
1 known investors
Find your way into Thyreos
Sign up to find every way you can get introduced to Thyreos
- Your email: who you already know at Thyreos, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Thyreos team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Thyreos develops recombinant herpesvirus-based vaccines for both animal and human health applications, designed to generate immune responses without affecting the nervous system. The company's platform targets herpesviruses that cause latent nervous system infections.
Investors · 1
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $297.5K |
| Department of Agriculture (USDA) | Phase I | 2022 | $174.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Thyreos do?
- Thyreos develops recombinant herpesvirus-based vaccines for both animal and human health applications, designed to generate immune responses without affecting the nervous system. The company's platform targets herpesviruses that cause latent nervous system infections.
- Who are Thyreos's investors?
- Thyreos's investors include Invest Nebraska.